Loading
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Regular session
$20.18
+$0.05 · +0.25%
Regular session · ET · Market data may be delayed.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Day range
Current $20.18
52-week range
Current $20.18
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
29
Expensive
Sentiment
74
Bullish
Risk
56
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Day range
Current $20.18
52-week range
Current $20.18
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI14.79M0.00%2.3T USD0.03%$380.78+0.32%
iShares Russell 2000 ETFIWM11M0.01%77.7B USD0.19%$278.1+0.19%
Vanguard Extended Market ETFVXF4.63M0.00%95.4B USD0.05%$233.98+0.36%
iShares Russell 2000 Growth ETFIWO3.85M0.03%14.04B USD0.24%$355.12+0.47%
Vanguard Russell 2000 ETFVTWO2.23M0.01%18B USD0.06%$112.33+0.21%
Fidelity Enhanced Small Cap ETFFESM2.06M0.03%6.41B USD0.28%$45.325+0.17%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS1.62M0.41%396.33M USD0.60%$106.61+0.80%
iShares Micro-Cap ETFIWC1.33M0.10%1.32B USD0.60%$182.69-0.06%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMInvesco Dorsey Wright SmallCap Momentum ETFDWASiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
